Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and ...

Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today ...

Spain's Naturgy plans to buy back almost 2.5-billion euros ($2.6 billion) of its shares, up to 10% of its capital, then ...

Travis Coy is using his Big Pharma bona fides to prioritize business development at the diversified and growing company.

Lebanon Plan Commission on Monday night unanimously approved a design plan for Eli Lilly and Co.’s $4.5 billion center for advanced manufacturing and drug development at the LEAP Research and ...

The 200-acre Lilly Medicine Foundry is expected to add 400 full-time jobs for highly skilled workers, including engineers, ...

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

Background Intravenous iron therapy with ferric derisomaltose (FDI) has been shown to improve outcomes in patients with heart ...

Questal Inc., the parent company of Questis, has raised $3.2 million in a Seed Series funding round led by top financial industry experts to accelerate the rollout of its AI-powered financial wellness ...

(Reuters) -Eli Lilly on Thursday suggested that demand for its popular diabetes and weight-loss treatments was not a concern, easing investor agitation about signs of weakness in sales of the drugs.

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast.